204 related articles for article (PubMed ID: 22592665)
1. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Suzuki H; Fujii Y; Ito M; Yoshida Y; Okada K; Soma M
Hypertens Res; 2012 Aug; 35(8):874-81. PubMed ID: 22592665
[TBL] [Abstract][Full Text] [Related]
2. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
3. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK;
N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041
[TBL] [Abstract][Full Text] [Related]
6. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
Sasaki H; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohhira M; Oyama T; Miyashita Y; Shirai K
J Atheroscler Thromb; 2009 Oct; 16(5):568-75. PubMed ID: 19749494
[TBL] [Abstract][Full Text] [Related]
9. Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus.
Seki Y; Morimoto S; Kimura S; Takano N; Yamashita K; Bokuda K; Sasaki N; Watanabe D; Ichihara A
Kidney Blood Press Res; 2023; 48(1):688-700. PubMed ID: 37866351
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Ando K; Ueshima K; Tanaka S; Kosugi S; Sato T; Matsuoka H; Nakao K; Fujita T
Int J Med Sci; 2013; 10(9):1209-16. PubMed ID: 23935398
[TBL] [Abstract][Full Text] [Related]
11. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.
Miyashita Y; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohira M; Oyama T; Shirai K
J Atheroscler Thromb; 2009 Oct; 16(5):621-6. PubMed ID: 19907103
[TBL] [Abstract][Full Text] [Related]
12. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Daikuhara H; Kikuchi F; Ishida T
Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
[TBL] [Abstract][Full Text] [Related]
14. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.
Fogari R; Derosa G; Zoppi A; Preti P; Lazzari P; Destro M; Fogari E; Rinaldi A; Mugellini A
Am J Hypertens; 2007 Apr; 20(4):417-22. PubMed ID: 17386350
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy.
Takenaka T; Nobe K; Okayama M; Kojima E; Nodaira Y; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
Clin Exp Hypertens; 2012; 34(4):243-8. PubMed ID: 22559034
[TBL] [Abstract][Full Text] [Related]
16. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.
Fogari R; Mugellini A; Zoppi A; Preti P; Maffioli P; Perrone T; Derosa G
Expert Opin Pharmacother; 2013 Mar; 14(4):371-84. PubMed ID: 23414196
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy.
Ogawa S; Nako K; Okamura M; Senda M; Mori T; Ito S
Hypertens Res; 2011 Mar; 34(3):400-1. PubMed ID: 21160485
[No Abstract] [Full Text] [Related]
18. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363
[TBL] [Abstract][Full Text] [Related]
19. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
[TBL] [Abstract][Full Text] [Related]
20. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA;
N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
